The decongestant are also called as nasal decongestant which are the type of pharmaceutical drug that is used to relieve nasal congestion in the upper respiratory tract. The active ingredients in the most decongestant is either pseudoephedrine or phenylephrine. Intranasal corticosteroids are also used as decongestant and anti-histamines may be also used to relieve runny nose, nasal itch and sneezing. Topical decongestants on topical application as dilute solution gives effect of vasoconstriction. Regular use of decongestant for longer duration is avoided as it causes atrophic rhinitis and insomnia because of vasoconstrictions.
The North America nasal decongestant market is witnessing lucrative growth during forecast period of 2021 to 2027. The decongestant are used in the treatment of nasal decongestions caused due to allergies, infections such as cold, influenza and sinus infections along with nasal polyps. The key factors such as rising demand for self-administrations of nasal decongestants is propelling growth of North America nasal decongestant market. Expansion of therapeutics application of nasal decongestant is also boosting growth of North America nasal decongestant market. However, compliance of inhaling nasal sprays is restraining growth of North America nasal decongestant market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the nasal decongestant market. In addition, complete analysis of changes on nasal decongestant expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The healthcare and pharmaceutical companies are going through high pressure for drug innovation to treat coronavirus in patients. The invention of vaccines by key players has lowered the pressure on the pharmaceutical companies to launch drugs for the novel infection. However, key players in nasal decongestant market are rising their R&D efforts. Due to these the nasal decongestant market have experienced positive impact during COVID-19 pandemics.
The North America nasal decongestant market is bifurcated by product type, application and country.
Product type like nasal strips, tablets, spray and capsules are comprised in the North America nasal decongestant market. In which nasal strips are also contributing in the growth of North America nasal decongest market. The nasal strips are also called as nasal dilators which are comprised of the band-aid type material and adhesive tape, which are encircle a hard plastic splint. Tightly spreading of nasal strips over the nose works to effectively lift the sides of the nostrils, opening nasal passage and increasing overall airflow. Nasal strips are proven their activities in nasal congestion and nasal snoring.
Applications such as asthma, cold and nasal allergies are comprised in the North America nasal decongestion market. In which cold segment is also contributing to the growth of the North America nasal decongestion market. The common cold is a type of viral infection of nose and throat (upper respiratory tract). It is usually harmless, while it might not feel the way, Various types of viruses can cause common cold. The sneezing, runny nose, cough, sore throat, headache, nasal congestion and fever are some of the symptoms of the common cold.
The North America nasal decongestion market is studied for key countries such as United States, Mexico and Canada. In which United States is anticipated to dominate the North America nasal decongestion market in 2020. The rising research and development activities in healthcare industries is propelling growth of North America nasal decongestion market. The rising disposable income of country is also boosting growth of North America nasal decongestion market. The growing cases of allergic rhinitis is also refuelling growth of North America nasal decongestion market.
The major key players in nasal decongestant market are 3M, Abbott Laboratories, Adapt Pharma Inc., Aegis Therapeutics Llc, Allergan Plc, Aptargroup Inc., Astrazeneca Plc, Bayer, Becton, Dickinson And Company, Cipla, Glaxosmithkline Plc, Innovus Pharmaceuticals Inc., Johnson & Johnson Services Inc., Meda Pharmaceuticals Inc., Merck & Co., Inc., Mylan N.V, Nastech Pharmaceutical Company Inc., Nidda Healthcare, Novartis Ag, Patrick Parsons, Pfizer Inc., Procter And Gamble, Rugby Laboratories and Sandoz International Gmbh among others.
November 2019, Sandoz announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Strengthening position in world’s third largest generics market.
June 2019: AptarGroup, Inc. acquired two pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC. The acquisitions are part of strategy to broaden its portfolio of services which supports pharmaceutical and biotech customers to accelerate their complex product development.
April 2019: Cipla Ltd. acquired 30% Stake in South African's Brandmed For Business Expansion. The Acquisition was carried out to pair the company’s strengths with Brandmed’s innovative, patient-centric approach to healthcare which will enhance Cipla Medpro’s portfolio.
December 2018: Procter & Gamble (P&G) completed the acquisition of Merck’s Consumer Health business. It is intended to improve P&G’s over the counter (OTC) geographic scale brand portfolio and category footprint across 15 markets.
The report analyses the nasal decongestant market based on product type, application and country. The various product type covered in the market are nasal strips, tablets, sprays and capsules. Based on application, the market is segmented into asthma, cold and nasal allergies. The report also analysed the impact of COVID-19 on the nasal decongestant market and it analyses that the healthcare and pharmaceutical companies are going through high pressure for drug innovation to treat coronavirus in patients. The invention of vaccines by key players has lowered the pressure on the pharmaceutical companies to launch drugs for the novel infection. However, key players in nasal decongestant market are rising their R&D efforts. Due to these the nasal decongestant market have experienced positive impact during COVID-19 pandemics. The study also imparts the major key players operating in the market.
Why to buy this report